Anti-Mouse VEGF Monoclonal Antibodies

PA007515.m2a: In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31), Mouse IgG2a Kappa

The in vivo grade recombinant anti-mouse VEGF mouse IgG2a kappa monoclonal antibody was produced in mammalian cells. 
Clone: G6-31.
Isotype: Mouse IgG2a Kappa.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: G6-31) specifically binds to mouse VEGF.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse VEGF protein. 
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse VEGF antibodies (clone of G6-31) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of anti-mouse VEGF antibody (Clone: G6-31):

1、Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors
Katsuhiro Miyajima et al. Acta Histochem Cytochem. 2010 May 1;43(2):33-44. doi: 10.1267/ahc.09034. Epub 2010 Apr 7. PMID: 20514290
“To investigate whether tumor development in E2-induced PRLoma is inhibited by anti-VEGF monoclonal antibody (G6-31), we evaluated tumor growth and observed the vascular structures. With simultaneous treatment with G6-31 for the latter three weeks of the 13-week period of E2 stimulation (E2+G6-31 group), the following inhibitory effects on the PRLoma were observed in the E2+G6-31 group as compared with the E2-only group. In the E2+G6-31 group, a tendency to reduction in pituitary weight was observed and significant differences were observed as (1) reductions in the Ki-67-positive anterior cells, (2) increases in TUNEL-positive anterior cells, and (3) repair of the microvessel count by CD34-immunohistochemistry. ”
Tags: anti-mouse VEGF G6-31; anti-mouse VEGF G6-31 mAb

2、Sprouting Angiogenesis in Human Pituitary Adenomas
Jie Zhou et al. Front Oncol. 2022 May 5:12:875219. doi: 10.3389/fonc.2022.875219. eCollection 2022.PMID: 35600354
“Anti-VEGF treatment has been demonstrated to successfully treat pituitary tumors in mouse models. Korsisaari et al. used the anti-VEGF antibody G6-31 to treat pituitary tumors in Men1+/- mice (53). After 67 days, they observed that G6-31 treatment reduced the tumor volume by 72% compared to the control group and significantly extended their survival. All pituitary tumors in Men1+/- mice were later identified as prolactinomas (53). The G6-31 antibody was also used to treat Drd2(-/-) mice with hyperplastic pituitary glands by Luque et al. (54). A group of female Drd2(-/-) mice were treated with G6-31 for six weeks (54). Pituitary hyperplasia was significantly reduced at the end of the treatment period compared to the placebo group. A reduction in MVD in G6-31 treated pituitary glands was also observed (54). Axitinib is a VEGF inhibitor targeting all three VEGF receptors (77), and it has been approved by the FDA to treat human renal cell carcinoma. Chauvet et al. tested axitinib on a transgenic mouse model expressing a truncated form of Hmga2 protein (55). Hmga2 mice develop prolactinomas between 9-11 months. Axitinib was administered to animals with a high circulating prolactin level for six weeks. At the end of the treatment period, they observed a significant reduction in tumor size and improvement in vascular structure (55). The main shortcomings of these studies were: 1) all tumors included in the treatment were prolactinomas, and 2) a small number of mice were used. For example, the survival curves after treatment in the study by Korsisaari et al. only included 8 and 9 mice for G6-31 and the control group, respectively (53). However, these studies suggest that the efficacy of such agents may merit investigation for the treatment of aggressive pituitary tumors.”
Tags: anti-mouse VEGF G6-31 in vivo; anti-mouse VEGF G6-31 in animal model

3、Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate anti-proliferative effects
Samuel A Blackman et al. bioRxiv [Preprint]. 2025 Oct 26:2025.10.25.684565. doi: 10.1101/2025.10.25.684565.PMID: 41306516
“This can occur via multiple mechanisms, including upregulation of placental growth factor 2 (PlGF-2), an alternative ligand for VEGF receptor 1 (VEGFR1) and neuropilin receptor 1 (NRP1). Activity of both growth factors is mediated by interactions with multiple receptors and extra-cellular matrix components, which complicates efforts to understand their contributions to cancer progression. To complement existing antibodies, we discovered those blocking interactions between PlGF-2 or VEGFA and their shared NRP1 receptor in the presence of heparin. Limiting angiogenesis to promote vascular normalization is one mechanism of anti-VEGF protection; here, anti-VEGFA antibodies blocking interactions with VEGFR1 and NRP1 reduced HUVEC tube formation in a physiological angiogenesis model. By contrast, antibodies binding PlGF-2 or VEGFA to block NRP1 significantly reduced proliferation of Caki-I kidney carcinoma cells in vitro, indicating this receptor mediates additional effects. ”
Tags: anti-mouse VEGF G6-31 antibody in cancer research; anti-mouse VEGF G6-31 in mouse tumor model

For more references about anti-mouse VEGF antibody (Clone: G6-31), please contact our scientific support team with message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody

Syd Labs provides the following anti-mouse VEGFA monoclonal antibodies:
In vivo grade recombinant anti-mouse VEGFA monoclonal antibodies (Clone B20-4.1.1.1))
In vivo grade recombinant anti-mouse VEGF-A monoclonal antibodies (Clone G6-31)
In vivo grade recombinant anti-mouse VEGF monoclonal antibodies (Clone G6-23)

Syd Labs provides the following anti-mouse PD-1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-1 / VEGF-A bispecific antibodies (Clone RMP1-14.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD1 / VEGFA bispecific antibodies (Clone 29F.1A12.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-23)
In vivo grade recombinant anti-mouse PD1 / VEGF bispecific antibodies (Clone 29F.1A12.1 / G6-23)
In vivo grade recombinant anti-mouse PD 1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-31)
In vivo grade recombinant anti-mouse PD-1 / VEGF A bispecific antibodies (Clone 29F.1A12.1 / G6-31)

Syd Labs provides the following anti-mouse PD-L1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-L1 / VEGF-A bispecific antibodies (Clone 10F.9G2.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-L1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-23)
In vivo grade recombinant anti-mouse PDL1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-31)

Syd Labs provides the following recombinant anti-mouse VEGF monoclonal antibodies for Flow Cytometry:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) for Flow Cytometry

Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Brolucizumab Biosimilar, research grade, VEGF-A Monoclonal Antibody
Faricimab Biosimilar, research grade, Human ANGPT2/VEGFA Monoclonal Antibody